Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial.
- DOI
- 10.1016/s1470-2045(26)00014-8
- Published
- 2026 May
- Container
- The Lancet. Oncology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s1470-2045-26-00014-8,
title = {Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial.},
author = {Morgans AK and Haresh KP and Jievaltas M and Olmos D and Shore ND and Vjaters E and Xing N and Mohamed AF and Littleton N and Srinivasan S and Verholen F and Saad F},
year = {2026},
journal = {The Lancet. Oncology},
doi = {10.1016/s1470-2045(26)00014-8},
url = {https://doi.org/10.1016/s1470-2045(26)00014-8}
}RIS
TY - JOUR TI - Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial. AU - Morgans AK AU - Haresh KP AU - Jievaltas M AU - Olmos D AU - Shore ND AU - Vjaters E AU - Xing N AU - Mohamed AF AU - Littleton N AU - Srinivasan S AU - Verholen F AU - Saad F PY - 2026 JO - The Lancet. Oncology DO - 10.1016/s1470-2045(26)00014-8 UR - https://doi.org/10.1016/s1470-2045(26)00014-8 ER -
APA
AK, M., KP, H., M, J., D, O., ND, S., E, V., N, X., AF, M., N, L., S, S., F, V., & F, S. (2026). Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(26)00014-8
Source records
- pubmed · retrieved 2026-09-26T00:43:15.134Z